Business Context and Reporting Period
Company: ICU Medical, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2007
Business Overview: ICU Medical is a leader in developing, manufacturing, and selling proprietary disposable medical connection systems for vascular therapy, primarily designed to prevent catheter-related bloodstream infections and needlestick injuries. The company also manufactures custom I.V. systems and critical care medical devices. Its principal product is the CLAVE needleless connector.
Key Financial Metrics (Year Ended Dec 31, 2007)
| Metric | 2007 | 2006 |
|---|---|---|
| Total Revenue | $188.1 million | $201.6 million |
| Net Income | $23.1 million | $25.7 million |
| Diluted EPS | $1.51 | $1.64 |
| Gross Margin | 42% | 40% |
| Operating Cash Flow | $41.5 million | $31.6 million |
| Cash & Marketable Securities | $95.6 million | $116.9 million |
| Working Capital | $131.8 million | $155.5 million |
| Total Debt | None reported | None reported |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 7% to $188.1 million from $201.6 million in 2006. This decline was primarily driven by a 13% drop in sales to the company's largest customer, Hospira ($129.7 million in 2007 vs. $148.4 million in 2006), due to lower unit sales and price reductions in critical care products under the Manufacturing, Commercialization and Distribution Agreement (MCDA).
- Product Mix Shift: While CLAVE sales increased slightly (6%), sales of critical care products (excluding custom) fell significantly. Conversely, custom I.V. system sales grew 13% to $45.3 million.
- Discontinued Products: The 2006 revenue included $14.6 million from products discontinued in late 2006 and early 2007 (Punctur-Guard and certain MCDA products), which contributed to the year-over-year revenue decrease.
- Profitability: Net income decreased 10% to $23.1 million. Gross margin improved to 42% from 40% as production inefficiencies experienced in late 2006 were resolved.
- Legal Charges: The company recorded a $5.0 million charge in "Other Income" (reducing net income) related to a court-ordered judgment for legal fees and costs in a patent infringement lawsuit against Alaris Medical Systems (Cardinal Health), which is currently under appeal.
Guidance, Outlook, and Risks
- 2008 Outlook: Management expects 2008 sales to Hospira to be comparable to 2007, with growth in CLAVE and custom I.V. systems offsetting declines in critical care products. Gross margin is estimated to approximate 45% in 2008. SG&A expenses are expected to rise to 26% of revenue due to increased sales personnel and compensation.
- Liquidity Risk (Auction Rate Securities): A significant portion of the company's marketable securities ($87.9 million as of Feb 11, 2008) consists of auction rate securities. Due to turbulence in credit markets, several auctions failed in February 2008, impairing liquidity. While the securities are investment-grade, the company may be unable to sell them to meet working capital needs without incurring losses.
- Customer Concentration: Hospira accounted for 73% of total revenue in 2007. The loss of this customer or a deterioration in the relationship would have a material adverse effect on the business.
- Manufacturing Expansion: The company is expanding operations in Mexico and plans to build a manufacturing plant in China (operational early 2009) to reduce costs and serve international markets.
- Patent Litigation: The company faces ongoing patent litigation risks, including the appeal of the Alaris judgment and new suits filed against RyMed Technologies.
Investor Verification Checklist
- Hospira Dependency: Verify the stability of the MCDA and supply agreements with Hospira, which represents nearly three-quarters of revenue.
- Auction Rate Securities Liquidity: Assess the current status of the $87.9 million portfolio of auction rate securities and the company's ability to access alternative credit lines if these assets remain illiquid.
- Legal Contingencies: Monitor the outcome of the appeal regarding the $5.0 million Alaris judgment and the status of the RyMed Technologies litigation.
- Margin Sustainability: Confirm whether the projected 45% gross margin for 2008 can be achieved amidst rising raw material costs (resins/plastics) and potential price pressures from competitors.
- International Expansion: Track the progress and cost efficiency of the new China manufacturing facility and the expansion of the Mexico operations.